Novartis’s MorphoSys acquisition comes with cancer drugs & antitrust questions

The latest stories trending on MedCity News.

Editor's Pick

Top Story Novartis's MorphoSys Acquisition Comes With Cancer Drugs & Antitrust Questions Novartis's €2.7B acquisition of MorphoSys brings two cancer drug candidates, one of which would give the pharmaceutical giant a way to stand apart from other myelofibrosis treatments. In a separate deal, MorphoSys sold to Incyte its rights to a partnered blood cancer drug. Sponsored Content Searching For an End-To-End Patient Tech Solution? Presented by Medidata Solutions Patient centricity requires empathy for and an understanding of the patient journey, from the initial diagnosis to clinical trial participation to receiving study results when the trial is completed.  Learn More. INVEST 2024 Value = Networking Connections, partnerships, funding, investments, plus top notch speakers and content - all of this and more is what you can expect from INVEST 2024. Hurry and save with the Super Early Bird Rate, but only until Feb 16th, then the price goes up. Register Now

Featured News

Eli Lilly Fatty Liver Drug Posts Promising Early Data, But Field Is Still Competitive Eli Lilly reported 74% of patients treated with tirzepatide achieved resolution of metabolic dysfunction-associated steatohepatitis, or MASH. However, the Phase 2 results showed only "clinically meaningful" improvement in resolving liver fibrosis, a key measure of the drug's potential competitiveness in a crowded field of contenders. Overcoming Hearing Healthcare Barriers to Realize Gene Therapy Promise The preliminary results from three clinical trials administering gene therapy to address deafness from otoferlin mutations mark inspiring and incredible progress in hearing healthcare. Ambience Healthcare Rakes In $70M for Documentation Tech That One Customer Calls 'Close to Perfection' SaaS startup Ambience Healthcare raised $70 million from investors including OpenAI, Andreessen Horowitz, Optum Ventures and Kleiner Perkins. The San Francisco-based company offers tools to alleviate clinicians' burnout by helping them with documentation, coding, referrals and after-visit summaries. Blue Cross Blue Shield of Massachusetts Introduces New Women's Health Offerings Blue Cross Blue Shield of Massachusetts has launched a new reproductive health care team and has partnered with Maven Clinic for 24/7 reproductive health support. What Primary Care's "Barnes & Noble Moment" Means for the Future of Digital Health Primary care is essential to living healthier lives, and we need all forms of it, from small local practices to big health systems and retail chains. Ultimately, it's going to be all primary care hands on deck, working together to make a lasting change for the health of Americans. Uncovering the Hidden Insights in Clinical Trial Documents: Critical Steps to Intelligent Document Processing In clinical trials, pharmaceutical companies are seeking to optimize operations and improve efficiency by automating […]

Resources

Affordable Surgical Robots In this MedCity Pivot Podcast episode, Anne Osdoit, CEO of Moon Surgical and Partner at European venture capital firm Sofinnova Partners, explains more about the Maestro System that Moon Surgical has built along with its unique business model. Listen Now

MedCity News • PO Box 901 • New York, NY unsubscribe